Argenx Overview

  • Year Founded
  • 2008

Year Founded

  • Status
  • Public

  • Employees
  • 2,009

Employees

  • Stock Symbol
  • ARGX

Stock Symbol

  • Investments
  • 7

  • Share Price
  • $970.60
  • (As of Friday Closing)

Argenx General Information

Description

Argenx is a Dutch biopharmaceutical company focused on developing antibody-based therapies for rare autoimmune diseases. The company's lead product, Vyvgart (efgartigimod), was approved by the FDA in December 2021 for the treatment of generalized myasthenia gravis (gMG). In 2022, Argenx also received FDA approval for Vyvgart Hytrulo, a subcutaneous formulation of Vyvgart, offering a more convenient option compared with Vyvgart's intravenous administration. In 2024, the FDA approved Vyvgart Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy, a rare immune-mediated neuromuscular disorder of the peripheral nervous system. Argenx is focused on innovation and developing its pipeline for treatments such as primary immune thrombocytopenia, thyroid eye disease, and Sjogren's Disease.

Contact Information

Website
www.argenx.com
Formerly Known As
Argenx N.V
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • Industriepark Zwijnaarde 7
  • Building
  • 9052 Zwijnaarde
  • Belgium
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Stock Exchange
BRU
Vertical(s)
Corporate Office
  • Industriepark Zwijnaarde 7
  • Building
  • 9052 Zwijnaarde
  • Belgium

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Argenx Stock Performance

As of 13-Nov-2026, Argenx’s stock price is $970.60. Its current market cap is $61B with 62.9M shares.

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$970.60 $983.66 $657.04 - $1.07K $61B 62.9M 89.1K $30.21

Argenx Financials Summary

As of 30-Sep-2026, Argenx has a trailing 12-month revenue of $5.82B.

In Thousands,
USD
TTM 30-Sep-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV 54,974,849 47,947,395 34,354,694 20,434,726
Revenue 5,821,482 4,153,482 2,190,231 1,226,316
EBITDA 1,147,700 (52,338) (299,669)
Net Income 1,877,035 1,292,035 833,040 (295,053)
Total Assets 8,682,698 6,202,522 4,542,458
Total Debt 0 47,160 39,053 20,000
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Argenx Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Argenx‘s full profile, request access.

Request a free trial

Argenx Patents

Argenx Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026233977-A1 Means and methods for detecting charcot-leyden crystals Pending 05-May-2025
GB-202506774-D0 Monovalent binding molecules and methods of use Pending 02-May-2025
WO-2026215434-A1 Methods of treating chronic inflammatory demyelinating polyneuropathy using liquid formulations of fcrn antagonists Pending 10-Apr-2025
GB-202500659-D0 Monovalent binding molecules and methods of use Inactive 17-Jan-2025
GB-202500663-D0 Monovalent binding molecules and methods of use Inactive 17-Jan-2025
To view Argenx’s complete patent history, request access »

Argenx Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Argenx Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Argenx‘s full profile, request access.

Request a free trial

Argenx Investments & Acquisitions (7)

Argenx’s most recent deal was a Merger/Acquisition with Unnatural Products for . The deal was made on 09-Nov-2026.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Unnatural Products 09-Nov-2026 Merger/Acquisition Drug Discovery
Forte Biosciences 27-Aug-2026 Merger/Acquisition Drug Discovery
Unnatural Products 11-Feb-2026 Later Stage VC Drug Discovery
OncoVerity 10-Dec-2024 Early Stage VC Drug Discovery
OncoVerity 27-Mar-2023 Early Stage VC Drug Discovery
You’re viewing 5 of 7 investments and acquisitions. Get the full list »

Argenx ESG

Risk Overview

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

Rank

Percentile

Pharmaceuticals

Industry

Rank

Percentile

Biotechnology

Subindustry

Rank

Percentile

To view Argenx’s complete esg history, request access »

Argenx Affiliates

Subsidiaries (6)

Name Industry Location Year Founded
Argenx Uk Gerrards Cross, United Kingdom 2022
Argenx Germany Munich, Germany 2021
Argenx France Issy-Les-Moulineaux, France 2021
Argenx Benelux Gent, Belgium 2020
Broteio Leiden, Netherlands 2013
You’re viewing 5 of 6 affiliates. Get the full list.  »

Argenx FAQs

  • When was Argenx founded?

    Argenx was founded in 2008.

  • Where is Argenx headquartered?

    Argenx is headquartered in Zwijnaarde, Belgium.

  • What is the size of Argenx?

    Argenx has 2,009 total employees.

  • What industry is Argenx in?

    Argenx’s primary industry is Biotechnology.

  • Is Argenx a private or public company?

    Argenx is a Public company.

  • What is Argenx’s stock symbol?

    The ticker symbol for Argenx is ARGX.

  • What is the current stock price of Argenx?

    As of 13-Nov-2026 the stock price of Argenx is $970.60.

  • What is the current market cap of Argenx?

    The current market capitalization of Argenx is $61B.

  • What is Argenx’s current revenue?

    The trailing twelve month revenue for Argenx is $5.82B.

  • What is Argenx’s annual earnings per share (EPS)?

    Argenx’s EPS for 12 months was $30.21.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process